Anti-GLDN antibodies are used in the immunodetection of the protein gliomedin. In humans, the canonical protein has a reported length of 551 amino acid residues and a mass of 59 kDa. Its subcellular localization is in the extracellular matrix and cell membrane. Up to 2 different isoforms have been reported for this protein. It is notably expressed in spinal cord, brain, placenta and sciatic nerve. GLDN is known to be involved with signal transduction pathways. Post-translational modifications have been described, including N-glycosylation and protein cleavage. The GLDN gene has been associated with the disease, Lethal congenital contracture syndrome. Synonyms for this target antigen include collomin and colmedin. GLDN gene orthologs have been reported in the mouse, rat, bovine, frog, zebrafish, chimpanzee and chicken species. Some GLDN antibodies may have been used in research and have associated citations. Western Blot is a widely used application for these antibodies. In addition, Immunofluorescence is also a common application.